|Bid||1.8400 x 100000|
|Ask||1.9750 x 100000|
|Day's Range||1.8450 - 1.8950|
|52 Week Range||1.5280 - 2.9663|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.32|
There is currently no cure for LS, therefore, routine screening that enables early detection and treatment of precancerous lesions has the potential to reduce the risk of CRC and to save lives. Approximately 95 percent of individuals with LS are unaware of their disease status, and nearly a third of patients who know their LS status fail to comply with the recommendation to undergo colonoscopy screening every one to two years.
– Data Presented at DDW 2019 Show 93.6% Acceptance Rate Among Patients Unwilling or Unable to Complete Other CRC Screening Tests – BERLIN and SAN DIEGO, May 19, 2019 --.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While it may not be enough for some shareholders, we think it is good to see the Epigenomics AG (F...